At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Nonindustrial source
- Class
- Mechanism of Action Endothelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Hypertension; Renal failure
Most Recent Events
- 19 Nov 1998 A study has been added to the Vascular Disorders pharmacodynamics section
- 02 Oct 1998 Discontinued-II for Renal failure in United Kingdom (Unknown route)
- 02 Oct 1998 Discontinued-Preclinical for Arrhythmias in Austria (Unknown route)